Viking Therapeutics (VKTX) reported late Wednesday a Q1 net loss of $0.41 per diluted share, compared with a loss of $0.26 a year earlier.
Analysts polled by FactSet expected a loss of $0.33.
No revenue was reported for the quarter ended March 31. The company held cash, cash equivalents, and short-term investments of $851.9 million at March 31, compared with $902.6 million on December 31, 2024.
The company's shares were down more than 1% in recent after-market activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。